Phase II trial of epirubicin in gastric cancer.


Patients with advanced inoperable or recurrent adenocarcinoma of the stomach received an iv bolus of epirubicin (75 mg/m2) every 3 weeks. Partial responses were observed in four of 24 evaluable patients (17%). Treatment was generally well tolerated; a drop in left ventricular ejection fraction was observed in one patient who had received 450 mg/m2 of… (More)


Cite this paper

@article{Scarffe1985PhaseIT, title={Phase II trial of epirubicin in gastric cancer.}, author={J. H.. Scarffe and J B Kenny and Russell J Johnson and Susan E. Owens and Geoffrey R. Giles and Stephen H. Leveson and William Maley}, journal={Cancer treatment reports}, year={1985}, volume={69 11}, pages={1275-7} }